Advertisement
Mayo Clinic Proceedings Home
MCP Digital Health Home

Erythromelalgia: A Review of Medical Management Options and Our Approach to Management

Published:December 02, 2022DOI:https://doi.org/10.1016/j.mayocp.2022.08.005

      Abstract

      Erythromelalgia (EM) is a rare disorder characterized by episodic, burning pain associated with erythema and warmth of the extremities. The feet and hands are most commonly affected. The pain can be so severe that patients may engage in behaviors, sometimes extreme, to cool the affected areas and change their lifestyle to avoid precipitating factors, such as exercise and increased ambient heat. A literature search was performed with PubMed and MEDLINE with the search term erythromelalgia. Inclusion criteria were studies on EM published after 1985 until January 1, 2022, in the English language and studies that provided information on medical treatment of EM. Studies were excluded if they were duplicates or did not include treatment data. No guidelines exist for the treatment of this complex disorder. Lifestyle modifications and pharmacologic treatments (topical and systemic) are discussed in this article, which provides a comprehensive review of published medical management options for erythromelalgia and a proposed approach to management.

      Abbreviations and Acronyms:

      EM (erythromelalgia), TEA (The Erythromelalgia Association)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Davis M.D.
        • O'Fallon W.M.
        • Rogers 3rd, R.S.
        • Rooke T.W.
        Natural history of erythromelalgia: presentation and outcome in 168 patients.
        Arch Dermatol. 2000; 136: 330-336
        • Yang Y.
        • Wang Y.
        • Li S.
        • et al.
        Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia.
        J Med Genet. 2004; 41: 171-174
        • Rush A.M.
        • Dib-Hajj S.D.
        • Liu S.
        • Cummins T.R.
        • Black J.A.
        • Waxman S.G.
        A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons.
        Proc Natl Acad Sci U S A. 2006; 103: 8245-8250
        • McDonnell A.
        • Schulman B.
        • Ali Z.
        • et al.
        Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile.
        Brain. 2016; 139: 1052-1065
        • Waxman S.G.
        • Dib-Hajj S.
        Erythermalgia: molecular basis for an inherited pain syndrome.
        Trends Mol Med. 2005; 11: 555-562
        • Burns T.M.
        • Te Morsche R.H.
        • Jansen J.B.
        • Drenth J.P.
        Genetic heterogeneity and exclusion of a modifying locus at 2q in a family with autosomal dominant primary erythermalgia.
        Br J Dermatol. 2005; 153: 174-177
        • Davis M.D.
        • Sandroni P.
        • Rooke T.W.
        • Low P.A.
        Erythromelalgia: vasculopathy, neuropathy, or both? A prospective study of vascular and neurophysiologic studies in erythromelalgia.
        Arch Dermatol. 2003; 139: 1337-1343
        • Ørstavik K.
        • Mork C.
        • Kvernebo K.
        • Jorum E.
        Pain in primary erythromelalgia—a neuropathic component?.
        Pain. 2004; 110: 531-538
        • Mantyh W.G.
        • Dyck P.J.
        • Dyck P.J.
        • et al.
        Epidermal nerve fiber quantification in patients with erythromelalgia.
        JAMA Dermatol. 2017; 153: 162-167
        • Mork C.
        • Kvernebo K.
        Erythromelalgia.
        in: Lebwohl M. Heymann W.R. Coulson I. Murrell D.F. Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 6th ed. Elsevier, 2022
        • Davis M.D.
        • Sandroni P.
        Lidocaine patch for pain of erythromelalgia.
        Arch Dermatol. 2002; 138: 17-19
        • Davis M.D.
        • Sandroni P.
        Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients.
        Arch Dermatol. 2005; 141: 1320-1321
        • Sandroni P.
        • Davis M.D.
        Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option?.
        Arch Dermatol. 2006; 142: 283-286
        • Poterucha T.J.
        • Weiss W.T.
        • Warndahl R.A.
        • et al.
        Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: a retrospective study of 36 patients at Mayo Clinic.
        J Drugs Dermatol. 2013; 12: 308-310
      1. AlgoTx. FDA grants ATX01 orphan drug designation in erythromelalgia. 2020.
      2. Capsaicin. IBM Micromedex Solutions.
        http://www.micromedexsolutions.com
        Date accessed: May 19, 2022
        • Muhiddin K.A.
        • Gallen I.W.
        • Harries S.
        • Pearce V.R.
        The use of capsaicin cream in a case of erythromelalgia.
        Postgrad Med J. 1994; 70: 841-843
        • Cohen J.S.
        Erythromelalgia: new theories and new therapies.
        J Am Acad Dermatol. 2000; (43(5)(pt 1)): 841-847
        • Low S.A.
        • Robbins W.
        • Tawfik V.L.
        Complex management of a patient with refractory primary erythromelalgia lacking a SCN9A mutation.
        J Pain Res. 2017; 10: 973-977
        • Davis M.D.
        • Morr C.S.
        • Warndahl R.A.
        • Sandroni P.
        Topically applied midodrine, 0.2%, an α1-agonist, for the treatment of erythromelalgia.
        JAMA Dermatol. 2015; 151: 1025-1026
        • Hou J.L.
        • Onajin O.
        • Gangat N.
        • Davis M.D.
        • Wolanskyj A.P.
        Erythromelalgia in patients with essential thrombocythemia and polycythemia vera.
        Leuk Lymphoma. 2017; 58: 715-717
        • Kurzrock R.
        • Cohen P.R.
        Erythromelalgia: review of clinical characteristics and pathophysiology.
        Am J Med. 1991; 91: 416-422
        • Calderone D.C.
        • Finzi E.
        Treatment of primary erythromelalgia with piroxicam.
        J Am Acad Dermatol. 1991; 24: 145-146
        • Pagani-Estevez G.L.
        • Sandroni P.
        • Davis M.D.
        • Watson J.C.
        Erythromelalgia: identification of a corticosteroid-responsive subset.
        J Am Acad Dermatol. 2017; 76: 506-511.e1
        • Cregg R.
        • Cox J.J.
        • Bennett D.L.
        • Wood J.N.
        • Werdehausen R.
        Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.
        Br J Pharmacol. 2014; 171: 4455-4463
        • Iqbal J.
        • Bhat M.I.
        • Charoo B.A.
        • Syed W.A.
        • Sheikh M.A.
        • Bhat I.N.
        Experience with oral mexiletine in primary erythromelalgia in children.
        Ann Saudi Med. 2009; 29: 316-318
        • Geha P.
        • Yang Y.
        • Estacion M.
        • et al.
        Pharmacotherapy for pain in a family with inherited erythromelalgia guided by genomic analysis and functional profiling.
        JAMA Neurol. 2016; 73: 659-667
        • Meijer I.A.
        • Vanasse M.
        • Nizard S.
        • Robitaille Y.
        • Rossignol E.
        An atypical case of SCN9A mutation presenting with global motor delay and a severe pain disorder.
        Muscle Nerve. 2014; 49: 134-138
        • Nwebube C.
        • Bulancea S.
        • Marchidann A.
        • Bello-Espinosa L.
        • Treidler S.
        Erythromelalgia: a child with V400M mutation in the SCN9A gene.
        Neurol Genet. 2021; 7: e570
        • Yang Y.
        • Adi T.
        • Effraim P.R.
        • Chen L.
        • Dib-Hajj S.D.
        • Waxman S.G.
        Reverse pharmacogenomics: carbamazepine normalizes activation and attenuates thermal hyperexcitability of sensory neurons due to Nav 1.7 mutation I234T.
        Br J Pharmacol. 2018; 175: 2261-2271
        • Goldberg Y.P.
        • Price N.
        • Namdari R.
        • et al.
        Treatment of Nav1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker.
        Pain. 2012; 153: 80-85
        • Cao L.
        • McDonnell A.
        • Nitzsche A.
        • et al.
        Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia.
        Sci Transl Med. 2016; 8: 335ra56
        • Kuhnert S.M.
        • Phillips W.J.
        • Davis M.D.
        Lidocaine and mexiletine therapy for erythromelalgia.
        Arch Dermatol. 1999; 135: 1447-1449
        • Nathan A.
        • Rose J.B.
        • Guite J.W.
        • Hehir D.
        • Milovcich K.
        Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment.
        Pediatrics. 2005; 115: e504-e507
        • Masic D.
        • Liang E.
        • Long C.
        • Sterk E.J.
        • Barbas B.
        • Rech M.A.
        Intravenous lidocaine for acute pain: a systematic review.
        Pharmacotherapy. 2018; 38: 1250-1259
        • Sheehy K.A.
        • Muller E.A.
        • Lippold C.
        • Nouraie M.
        • Finkel J.C.
        • Quezado Z.M.
        Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study.
        BMC Pediatr. 2015; 15: 198
        • Montoya L.
        • Adams A.C.
        • Popenhagen M.P.
        • Russi D.C.
        • Singhal N.R.
        • Price H.N.
        Intravenous ketamine infusion as an adjunctive pain treatment for erythromelalgia: a pediatric case report.
        A A Pract. 2022; 16: e01582
        • Moody S.
        • Pacheco S.
        • Butler I.J.
        • Koenig M.K.
        Secondary erythromelalgia successfully treated with intravenous immunoglobulin.
        J Child Neurol. 2012; 27: 922-923
        • Jackson A.L.
        • Oates J.A.
        A patient with adult erythermalgia: evidence suggesting an autoimmune etiology.
        Am J Med Sci. 2008; 335: 320-322
        • Moiin A.
        • Yashar S.S.
        • Sanchez J.E.
        • Yashar B.
        Treatment of erythromelalgia with a serotonin/noradrenaline reuptake inhibitor.
        Br J Dermatol. 2002; 146: 336-337
        • Rey J.
        • Cretel E.
        • Jean R.
        • Pastor M.J.
        • Durand J.M.
        Serotonin reuptake inhibitors, Raynaud's phenomenon and erythromelalgia.
        Rheumatology (Oxford). 2003; 42: 601-602
        • Herskovitz S.
        • Loh F.
        • Berger A.R.
        • Kucherov M.
        Erythromelalgia: association with hereditary sensory neuropathy and response to amitriptyline.
        Neurology. 1993; (43(3)(pt 1)): 621-622
      3. Gabapentin. IBM Micromedex Solutions.
        http://www.micromedexsolutions.com
        Date accessed: May 19, 2022
        • McGraw T.
        • Kosek P.
        Erythromelalgia pain managed with gabapentin.
        Anesthesiology. 1997; 86: 988-990
      4. Pregabalin. IBM Micromedex Solutions.
        http://www.micromedexsolutions.com
        Date accessed: May 19, 2022
        • Metwali H.
        • Hasan H.
        • Yousuf M.
        Pregabalin induced syndrome of inappropriate anti-diuretic hormone (SIADH) secretion: a case report.
        J Basic Clin Pharm. 2019; 10: 12-14
        • Kalava K.
        • Roberts C.
        • Adair J.D.
        • Raman V.
        Response of primary erythromelalgia to pregabalin therapy.
        J Clin Rheumatol. 2013; 19: 284-285
        • Poddar K.
        • Gulati R.
        Managing late onset primary erythromelalgia with oral pregabalin.
        Int J Rheumatol Clin Immunol. 2017; 5: CS1
        • Kalgaard O.M.
        • Mork C.
        • Kvernebo K.
        Prostacyclin reduces symptoms and sympathetic dysfunction in erythromelalgia in a double-blind randomized pilot study.
        Acta Derm Venereol. 2003; 83: 442-444
        • Mork C.
        • Salerud E.G.
        • Asker C.L.
        • Kvernebo K.
        The prostaglandin E1 analog misoprostol reduces symptoms and microvascular arteriovenous shunting in erythromelalgia—a double-blind, crossover, placebo-compared study.
        J Invest Dermatol. 2004; 122: 587-593
        • Thami G.P.
        • Bhalla M.
        Erythromelalgia induced by possible calcium channel blockade by ciclosporin.
        BMJ. 2003; 326: 910
        • Sunahara J.F.
        • Gora-Harper M.L.
        • Nash K.S.
        Possible erythromelalgia-like syndrome associated with nifedipine in a patient with Raynaud's phenomenon.
        Ann Pharmacother. 1996; 30: 484-486
        • Cohen J.S.
        High-dose oral magnesium treatment of chronic, intractable erythromelalgia.
        Ann Pharmacother. 2002; 36: 255-260
        • Al-Minshawy S.M.
        • El-Mazary A.A.
        An Egyptian child with erythromelalgia responding to a new line of treatment: a case report and review of the literature.
        J Med Case Rep. 2014; 8: 69
        • Sakakibara R.
        • Fukutake T.
        • Kita K.
        • Hattori T.
        Treatment of primary erythromelalgia with cyproheptadine.
        J Auton Nerv Syst. 1996; 58: 121-122
        • Guillet M.H.
        • Le Noach E.
        • Milochau P.
        • Sassolas B.
        • Guillet G.
        [Familial erythermalgia treated with pizotifen].
        Ann Dermatol Venereol. 1995; 122: 777-779
      5. Giaimo JD, Paulk KL, Phelan HA, Lau FH, Grieshaber EB, Carter JE. Remission of pain from frostbite and erythromelalgia with epidural infusion of ropivacaine: results of a two-year follow-up. Am Surg. Published online December 14, 2020. https://doi.org/10.1177/0003134820956923

        • D'Angelo R.
        • Cohen I.T.
        • Brandom B.W.
        Continuous epidural infusion of bupivacaine and fentanyl for erythromelalgia in an adolescent.
        Anesth Analg. 1992; 74: 142-144
        • Mohr M.
        • Schneider K.
        • Grosche M.
        • Hildebrandt J.
        [Cervical epidural infusion of morphine and bupivacaine in severe erythromelalgia].
        Anasthesiol Intensivmed Notfallmed Schmerzther. 1994; 29: 371-374
        • Rauck R.L.
        • Naveira F.
        • Speight K.L.
        • Smith B.P.
        Refractory idiopathic erythromelalgia.
        Anesth Analg. 1996; 82: 1097-1101
        • Stricker L.J.
        • Green C.R.
        Resolution of refractory symptoms of secondary erythermalgia with intermittent epidural bupivacaine.
        Reg Anesth Pain Med. 2001; 26: 488-490
        • Chinn G.
        • Guan Z.
        Case report and literature review: interventional management of erythromelalgia.
        Transl Perioper Pain Med. 2019; 6: 91-97
        • Harrison C.M.
        • Goddard J.M.
        • Rittey C.D.
        The use of regional anaesthetic blockade in a child with recurrent erythromelalgia.
        Arch Dis Child. 2003; 88: 65-66
        • Lee C.E.
        • Paulk K.
        • Garvie K.
        • Grieshaber E.
        • Carter J.
        • Ball B.
        Pediatric erythromelalgia treated with epidural ropivacaine infusion.
        JAAD Case Rep. 2019; 5: 306-308
        • Li X.
        • Li Y.
        • Qu Y.
        • Lu L.
        Secondary erythromelalgia successfully treated with patient-controlled epidural analgesia and interferon α-2b: a case report and review of the literature.
        Exp Ther Med. 2016; 11: 1823-1826
        • Seishima M.
        • Kanoh H.
        • Izumi T.
        • et al.
        A refractory case of secondary erythermalgia successfully treated with lumbar sympathetic ganglion block.
        Br J Dermatol. 2000; 143: 868-872
        • Wang W.H.
        • Zhang L.
        • Dong G.X.
        • et al.
        Chemical lumbar sympathectomy in the treatment of recalcitrant erythromelalgia.
        J Vasc Surg. 2018; 68: 1897-1905
        • Zhang L.
        • Wang W.H.
        • Li L.F.
        • et al.
        Long-term remission of primary erythermalgia with R1150W polymorphism in SCN9A after chemical lumbar sympathectomy.
        Eur J Dermatol. 2010; 20: 763-767
        • Gaur S.
        • Koroscil T.
        Late-onset erythromelalgia in a previously healthy young woman: a case report and review of the literature.
        J Med Case Rep. 2009; 3: 106
        • Durosaro O.
        • Davis M.D.
        • Hooten W.M.
        • Kerkvliet J.L.
        Intervention for erythromelalgia, a chronic pain syndrome: comprehensive pain rehabilitation center, Mayo Clinic.
        Arch Dermatol. 2008; 144: 1578-1583